Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Halozyme Therapeutics's EV/EBITDA was 22.2× on Nov 11, 2026, against 12.7× a year earlier. Over the last 5 years it ranged from 12.0× to 35.3×, with a median of 19.8×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 22.2× | +10.2 |
| 2025 | Dec 31, 2025 | 12.0× | −3.2 |
| 2024 | Dec 31, 2024 | 15.2× | −3.7 |
| 2023 | Dec 29, 2023 | 19.0× | −16.2 |
| 2022 | Dec 30, 2022 | 35.1× | +18.7 |
| 2021 | Dec 31, 2021 | 16.5× | −126.3 |
| 2020 | Dec 31, 2020 | 142.8× | +102.5 |
| 2019 | Jan 31, 2019 | 40.2× | +3.8 |
| 2018 | Dec 31, 2018 | 36.4× | – |
See a number that looks wrong?